Insider buying last 90 days
No open-market insider purchases were filed for STOK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every STOK insider filing, plotted on the chart in Gekko.Open STOK in Gekko
NASDAQ: STOK
Stoke Therapeutics (STOK) Stock Analysis & Forecast
Oct 12 close
$24.15−0.59 (−2.4%)
Gekko Brief
AI summaryOct 12 closeThis week's attention centers on Stoke Therapeutics presenting preclinical and early clinical data for STK-002, an experimental treatment for autosomal dominant optic atrophy, at the American Academy of Ophthalmology 2026 Annual Meeting. ADOA is a rare inherited optic nerve disorder with no approved treatments, caused by OPA1 gene variants. Separately, short interest was reported at 19.72% of public float as of September 30, 2026, with a short interest ratio of 10.2 days to cover, up 3.19% from the prior report. Analyst coverage remains entirely positive, with 9 firms rating the stock buy and a consensus target of $46.46.
Shares closed at $24.15, down 2.4%, sitting below both the 50-day average of $29.31 and the 200-day average of $31.41, with the 50-day below the 200-day. The stock has fallen 16.8% over one month, 17.1% over three months, and 31.1% over six months. The GekkoIndex reads 67.4, placing it in the Accumulation zone, while the price sits 32.5% below Gekko Fair Value of $35.8.
Earnings are scheduled for 3 November 2026, 21 days out, falling inside a typical 20-trading-day holding window; the prior report showed an EPS miss, with actual of -$0.97 against a -$0.71 estimate, and a -4.9% reaction. No insider, Congress, or unusual options activity appears in their respective windows, and one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged a 4.1% gain over 5 years, rising in 3 of them, a factor worth weighing against the pending earnings date and a typical 20-day move of 12.6%.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Stoke Therapeutics price vs fair value
Close $24.15200-day averageGekko Fair Value $35.80
Stoke Therapeutics quick facts
- Market cap
- $1.56B
- P/E ratio
- —
- Forward P/E
- 204.1
- EPS, TTM
- −$3.33
- Revenue, TTM
- $27.59M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.26
- Volume
- 372,983 avg 808,297
- 1-year return
- −19.2%
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.6%
- 50-day average
- $29.31
- 200-day average
- $31.41
- Next earnings
- Nov 3
- Shares outstanding
- 64.53M
Stoke Therapeutics swing-trade checklist
Stoke Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $24.15 is below the 50-day ($29.31) and 200-day ($31.41) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.4, Accumulation
Reading 67.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
32.5% below
Price is 32.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.1% on average
From this point in the calendar, the next 20 trading days averaged +4.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Stoke Therapeutics stock chart and price history
Stoke Therapeutics closed at $24.15 on Oct 12, 2026, −19.2% over the past year, inside a 52-week range of $20.32 to $40.22.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −16.8%
- 3 months
- −17.1%
- 6 months
- −31.1%
- 1 year
- −19.2%
The full STOK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open STOK in Gekko
Follow Stoke Therapeutics through every session
Put STOK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track STOK in GekkoFree for 7 days. No credit card required.
About Stoke Therapeutics
Stoke Therapeutics is a biopharmaceutical company working on antisense oligonucleotide therapies aimed at the root causes of serious genetic disorders. Its work centers on a proprietary technology called TANGO, which is used to design ASOs that boost protein expression in the body. The company is best known for STK-001, its lead candidate now in Phase I/IIa trials for Dravet syndrome, a severe form of genetic epilepsy.
Beyond its lead program, Stoke Therapeutics is advancing STK-002 through preclinical work as a potential treatment for autosomal dominant optic atrophy. The company has also entered into a licensing and collaboration arrangement with Acadia Pharmaceuticals to pursue RNA-based medicines for rare and serious neurodevelopmental conditions affecting the central nervous system. Its therapeutic efforts are concentrated largely within the United States.
Originally established under the name ASOthera Pharmaceuticals, the company took on its current name, Stoke Therapeutics, in May 2016, having been founded in 2014. It is headquartered in Bedford, Massachusetts, and its shares are listed on the NASDAQ under the ticker STOK.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- stoketherapeutics.com
Stoke Therapeutics GekkoIndex: the smart money zone
Stoke Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.4, in the Accumulation zone, down 0.9 points over five sessions.
67.4Accumulation
Down 0.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | Not available | |||
| Accumulation (current zone) | 217 | +2.2% | +7.2% | ||
| Neutral | 392 | +1.8% | +6.5% | ||
| Distribution | 39 | +2.6% | +12.3% | ||
| Selling | 7 | Too few readings yet | |||
Average STOK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the STOK price, zone by zone.Track STOK in Gekko
Is Stoke Therapeutics stock overvalued? Gekko Fair Value
Stoke Therapeutics trades 32.5% below Gekko Fair Value of $35.80, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Stoke Therapeutics shares are worth, recalculated every trading day.
$35.80
Gekko Fair Value, Oct 10, 2026
32.5% Undervalued
At the end of Aug 2026 the price was 24.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open STOK in Gekko
Stoke Therapeutics insider and Congress trading
No open-market insider purchases were filed for Stoke Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in STOK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for STOK, plotted on the chart in Gekko.Open STOK in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds STOK.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Stoke Therapeutics earnings: next date and track record
Stoke Therapeutics reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
22 days away
- EPS estimate
- −$0.93
- Revenue estimate
- $8.21M
6 of 8reports beat the EPS estimate
±7.8%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 11, 2026 | −$0.97 est −$0.71 | — | −4.9% |
| Nov 4, 2025 | −$0.65 est −$0.54 | $10.63M est $4.56M | −12.6% |
| Aug 12, 2025 | −$0.40 est −$0.57 | $13.82M est $5.36M | +28.5% |
| May 5, 2025 | $1.90 est −$0.09 | $158.6M est $31.51M | −9.1% |
| Mar 24, 2025 | −$0.18 est −$0.53 | — | −5.0% |
| Nov 5, 2024 | −$0.47 est −$0.53 | $4.89M est $4.20M | +1.1% |
| Aug 7, 2024 | −$0.46 est −$0.56 | $4.83M est $3.26M | −0.6% |
| May 6, 2024 | −$0.57 est −$0.61 | $4.22M est $3.21M | −0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Stoke Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Stoke Therapeutics is $46.46, +92.4% from the last close, from 9 firms rating the stock in the last 90 days.
$46.46consensus 12-month target, +92.4% from the last close
Now $24.15Avg $46.46
Low $35High $60
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | BTIG | $39 | +61.5% |
| Aug 21 | J.P. Morgan | $40 | +65.6% |
| Aug 12 | Canaccord Genuity | $58 | +140.2% |
| Aug 4 | H.C. Wainwright | $50 | +107.0% |
| Aug 4 | TD Cowen | $60 | +148.4% |
+7.2%average 20-day move after past Accumulation readings
+4.1%average move over the next 20 trading days in the last 5 years
±5.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Stoke Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Stoke Therapeutics averaged +4.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.1% | 3 of 5 |
| Next 10 trading days | +4.6% | 4 of 5 |
| Next 15 trading days | +6.0% | 3 of 5 |
| Next 20 trading days | +4.1% | 3 of 5 |
| Next 30 trading days | −2.8% | 1 of 5 |
For scale, STOK’s typical 20-trading-day move in either direction is about 12.6%.
Stoke Therapeutics market cap and key statistics
Stoke Therapeutics’s market cap is $1.56B and revenue of $27.59M over the last twelve months.
Valuation
- Market cap
- $1.56B
- Forward P/E
- 204.1
- EPS, TTM
- −$3.33
- Gekko Fair Value
- $35.80
Trading
- Volume
- 372,983
- Avg volume, 20 days
- 808,297
- 52-week high
- $40.22
- 52-week low
- $20.32
- Shares outstanding
- 64.53M
Financials
- Revenue, TTM
- $27.59M
- Profit margin
- 0%
- Return on equity
- -61.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.26
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.6%
Stoke Therapeutics stock news this week
Coverage of Stoke Therapeutics this week reads positive: 7 positive, 3 neutral and 1 negative headlines.
- Stoke Therapeutics shares STK-002 data for eye disorder at AAOStreetInsider, Oct 12
- Stoke Therapeutics presents data on ADOA treatment STK-002 By Investing.comInvesting.com Canada, Oct 12
- Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire, Oct 12
- Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Oct 2026MarketBeat, Oct 10
- Stoke Therapeutics Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 8
- Stoke Therapeutics (STOK) Could Be 46% Below Fair Value As Clinical Catalysts BuildSimply Wall Street, Oct 7
Stoke Therapeutics peers
Stoke Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Stoke Therapeutics stock FAQ
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $1.56B at the Oct 12, 2026 close of $24.15, with 64.53M shares outstanding.
What is the Stoke Therapeutics stock forecast?
The consensus analyst 12-month price target for Stoke Therapeutics is $46.46, +92.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Stoke Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Stoke Therapeutics is undervalued: the Oct 12, 2026 close of $24.15 is 32.5% below Gekko Fair Value of $35.80. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Stoke Therapeutics report earnings next?
Stoke Therapeutics is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of −$0.93 per share on revenue of $8.21M. Stoke Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 7.8% on average across the report.
What is Stoke Therapeutics’s 52-week high and low?
Stoke Therapeutics’s 52-week high is $40.22 and its 52-week low is $20.32; it closed at $24.15 on Oct 12, 2026, −19.2% over the past year.
Is Stoke Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Stoke Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.